Genomic Health, Inc. (Nasdaq: GHDX) announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center. All of the studies analyze the company's Oncotype DX® breast cancer test, which is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for women with early-stage breast cancer...
More...
More...